We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
(+20%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-0.22%
Top 10 Holdings %
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$54.7M |
| 2 |
EAR
Eargo, Inc. Common Stock
EAR
|
+$37.9M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$37.2M |
| 4 |
SPRB
Spruce Biosciences
SPRB
|
+$36M |
| 5 |
Pulmonx
LUNG
|
+$24.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$135M |
| 2 |
Centene
CNC
|
+$37.5M |
| 3 |
Baxter International
BAX
|
+$27.2M |
| 4 |
Assembly Biosciences
ASMB
|
+$24.1M |
| 5 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.97% |
| 2 | Consumer Staples | 1.52% |
| 3 | Consumer Discretionary | 0.76% |
| 4 | Industrials | 0.46% |
| 5 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IGMS
151
DELISTED
IGM Biosciences
IGMS
| – | – |
-19,762
| Closed | -$1.46M |
|
152
Passage Bio
PASG
$13.9M
| – | – |
-10,302
| Closed | -$2.7M |
|
153
Vertex Pharmaceuticals
VRTX
$133B
| – | – |
-9,000
| Closed | -$2.45M |
|
|
OBSV
154
DELISTED
ObsEva SA Ordinary Shares
OBSV
| – | – |
-1,434,652
| Closed | -$3.56M |
|
|
RDUS
155
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-814,208
| Closed | -$9.23M |
|
|
BMY.RT
156
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| – | – |
-185,150
| Closed | -$417K |
|
|
NBRV
157
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| – | – |
-4,271
| Closed | -$569K |
|
|
IMMU
158
DELISTED
Immunomedics Inc
IMMU
| – | – |
-1,587,500
| Closed | -$135M |
|
|
MNTA
159
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| – | – |
-400,000
| Closed | -$21M |
|
|
ZGNX
160
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-415,982
| Closed | -$7.46M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
- Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
- Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
- Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
- Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
- Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
- Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.
Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.